The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers  by Zhang, Suping et al.
The American Journal of Pathology, Vol. 181, No. 6, December 2012
Copyright © 2012 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ajpath.2012.08.024Short Communication
The Onco-Embryonic Antigen ROR1 Is Expressed
by a Variety of Human CancersSuping Zhang,* Liguang Chen,*
Jessica Wang-Rodriguez,* Ling Zhang,* Bing Cui,*
Wendy Frankel,† Rongrong Wu,* and
Thomas J. Kipps*
From the Moores UCSD Cancer Center,* University of California,
San Diego, San Diego, California; and the Ohio State University
Medical Center,† Columbus, Ohio
ROR1 is an orphan-receptor tyrosine-kinase-like sur-
face antigen that is expressed by many tissues during
embryogenesis, some B-cell malignancies, and vari-
ous cancer cell lines but not by virtually all normal
adult tissues. Here, we report that large proportions
of many different human cancers also express ROR1,
particularly those cancers that have high-grade his-
tology. Primary cancers that expressed ROR1 more
commonly expressed high levels of phosphorylated
AKT (p-AKT) and phosphorylated cAMP response el-
ement binding-factor (p-CREB) than similar cancers
that lacked expression of ROR1. Induced expression
of ROR1 could enhance basal p-AKT and p-CREB levels
and could promote the growth of a cancer cell line,
MEC1. Conversely, silencing ROR1 resulted in lower
levels of p-AKT and p-CREB, which was associated
with impaired tumor cell growth. In summary, this
study found that many different human cancers ex-
press ROR1 and that ROR1 may play a functional role
in promoting tumor cell growth, suggesting that this
orphan-receptor tyrosine-kinase-like protein may be
a potential target for therapy directed against a va-
riety of human cancers. (Am J Pathol 2012, 181:
1903–1910; http://dx.doi.org/10.1016/j.ajpath.2012.08.024)
ROR1 is a type I orphan-receptor tyrosine-kinase-like sur-
face protein that is expressed during embryogenesis and
by certain leukemias and lymphomas but not on virtually
all normal adult tissues.1–6 Some patients treated with
vaccines of autologous leukemia cells genetically engi-
neered to promote antileukemia immune responses gen-
erated autoantibodies specific for ROR1 that did not re-
act with nontumor tissues.4 As such, ROR1 is consideredan onco-embryonic antigen that currently is being tar-
geted for immune therapy of patients with leukemias that
express this surface antigen.7
More recent studies found that many human breast ad-
enocarcinomas also expressed high levels of ROR1, which
was not expressed by normal breast tissue.8 Expression of
ROR1 appeared to contribute to activation of AKT and
cAMP response element-binding factor (CREB) and was
associated with enhanced tumor cell growth.8 The associ-
ation between ROR1 with activated AKT also was noted in
another study, which also found that ROR1 could associate
with epidermal growth factor receptor, thereby enhancing
signaling in response to relevant ligands.9
In this study, we used a high-affinity monoclonal antibody
(mAb) highly specific for ROR1 (named 4A54) to examine
for expression of this onco-embryonic antigen in other hu-
man cancers. In addition, we examined cancer cell lines
and primary human lung, ovarian, and pancreatic cancer
tissues for expression of phospho-AKT and phospho-CREB
to define whether expression of ROR1 was associated with
activated AKT/CREB in other human cancers.
Materials and Methods
Cell Culture
Cancer cell lines were purchased from American Type
Culture Collection (Manassas, VA) and cultured at 37°C
in a 5% CO2/95% humidified air incubator in Dulbecco’s
modified Eagle medium (Invitrogen, Carlsbad, CA) or
RPMI 1640 (Gibco, Carlsbad, CA) with 10% fetal bovine
serum (Invitrogen). Puromycin (1 g/mL) or G418 (1.5
g/mL) were used for selection of stable transfectants.
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The project was reviewed and approved by one of the
Institutional Review Boards of the University of California,
San Diego, in accordance with the requirements of the
Code of Federal Regulations on the Protection of Human
subjects (45 CFR 46 and 21 CFR 50 and 56), including its
relevant subparts (IRB no.080918). Tissue microarray
slides were purchased from the National Development
and Research Institutes, Inc. (Pan-cancer tissue microas-
say slides; NDRI, New York, NY) or the Cooperative Hu-
man Tissue Network (OvCa1; CHTN, Nashville, TN) Tis-
sue Microarray, or were generated by Dr. Wendy Frankel
(Ohio State University, Columbus, OH; see Supplemental
Tables S1–S7 at http://ajp.amjpathol.org). Immunohisto-
chemistry (IHC) was performed to detect ROR1, p-AKT, or
p-CREB with the use of the streptavidin-biotin method as
described in prior study.8 The level of ROR1, p-AKT, or
p-CREB was scored on the following scale: 0 (nega-
tive) indicates that none of the cells within the sample
bound to the antibody;  (moderate) indicates low-level
binding of the mAb to tumor cells or moderate-level bind-
ing of the mAb to 50% of the tumor cells;  (strong)
indicates moderate-level staining by 50% of the tumor
cells or high-level staining of the tumor cells. A board-
certified pathologist (J.W.-R.) scored each tissue mi-
croarray in a blinded fashion.
Flow Cytometry
Cells were stained with 4A5 conjugated with Alexa 647
(Alex 647-4A5) to detect surface ROR1. For cytoplasmic
staining, the cells were fixed with paraformaldehyde and
processed as described before staining the cells with
anti-phosphoserine-133 CREB conjugated with Alexa-
488 (Alex488-anti-p-CREB), or anti-phosphoserin-473
AKT conjugated with phycoerythrin (PE-anti-p-AKT).
Stained cells were analyzed with a FACSCalibur (Becton
Dickinson, San Jose, CA). Mean fluorescence intensity of
each stained population was determined with FlowJo
software version 6.4.7 (TreeStar, Inc., Ashland, OR). For
analysis of cell DNA content, the cells were fixed in 70%
ethanol before staining with propidium iodide (Sigma-
Aldrich, St. Louis, MO). Sub-G1 apoptotic cells were cal-
culated for analysis of cell survival. Viable single cells
were analyzed for cell cycle distribution. Propidium io-
dide also was used to stain nonfixed, viable cells to
examine for their capacity to exclude this dye, a measure
of cell viability.
Silencing of Human ROR1
We used the Virapower lentivirus expression system (In-
vitrogen) to express short hairpin RNA (shRNA). ROR1
shRNA1, ROR1 shRNA2, or nonspecific control shRNA
(Control) were purchased from Open Biosystems (Rock-
ford, IL). The sequence of each shRNA is as follows:
5=-CTCATTTAGCAGACATCGCAA-3= (shRNA1), 5=-CTT-
TACTAGGAGACGCCAATA-3= (shRNA2), and 5=-AGCG-
GACTAAGTCCATTGC-3= (Control).Cell Proliferation Assay
Cell proliferation was analyzed with Cell-Counting Kit So-
lution (CCK-8) (Dojindo, Kumamoto, Japan). Cells were
plated in 96-well plates at 1 to 5  103 cells/well and
maintained at 37°C in a humidified incubator. CCK-8 (10
L) was added to each well at different time points, and
the cells were cultured for an additional 3 hours. The
absorbance at 450 nm was measured to calculate the
numbers of viable cells in each well.
Statistical Analysis
Statistical significance of the differences among various
histologic subtypes and phenotypic subtype of various
cancers was analyzed with the Kruskal–Wallis test. The
correlation between expression of ROR1 and expression of
p-AKT/p-CREB was analyzed with the Fisher’s exact test
and Pearson coefficiency. A one-way analysis of variance
followed by Dunnett’s multiple comparisons test was used
to evaluate the statistical difference in rates of proliferation
for cells. All analyses were performed with GraphPad Prism
software version 5 (GraphPad Software, La Jolla, CA). A P
value of 0.05 was considered significant.
Results
Expression of ROR1 in Human Cancer
We examined for expression of ROR1 by various cancer
cell lines by immunoblot analysis, immune-precipitation
assays, and flow cytometry. Chinese hamster ovary
(CHO) cells and CHO cells transduced to express human
ROR1 (CHO-ROR1) were used as negative and positive
control, respectively.4 We found that 50% of the cell
lines examined expressed surface ROR1 at different lev-
els by flow cytometry (Figure 1A; see also Supplemental
Figure S1A and Supplemental Table S8 at http://ajp.
amjpathol.org). Lysates from each cancer cell line that
had detectable surface ROR1 also had proteins of 125
kDa and 100 kDa detectable by immunoblot analysis
with the use of commercially available rabbit anti-ROR1
antibodies. Immune-precipitation analysis of these same
lysates with the use of the 4A5 mAb identified only the
125-kDa band (Figure 1A; see also Supplemental Figure
S1A at http://ajp.amjpathol.org). Lysates prepared from
primary tumor tissues such as adenocarcinomas of the
colon or bladder also had ROR1 detectable by immuno-
blot analysis (Figure 1B).
We prepared cytospin slides of ROR1 MDA-MB-231
cells to determine whether fixation in either paraformal-
dehyde or formalin affected the immunohistochemical
staining pattern observed with 4A5. Although 4A5 de-
tected the 125-kDa isoform found expressed on the
plasma membrane of MDA-MB-231 cells (see Supple-
mental Figure S1B at http://ajp.amjpathol.org), we found
that the apparent subcellular location of ROR1 in these
cells was differentially affected by the fixation solution
used to prepare the slide. We detected ROR1 promi-
nently located at the cell membrane when the cells were
fixed in paraformaldehyde. However, we detected mostly
dicated
The Expression of ROR1 in Human Cancers 1905
AJP December 2012, Vol. 181, No. 6cytoplasmic ROR1 in formalin-fixed cells (see Supple-
mental Figure S1B at http://ajp.amjpathol.org). Neverthe-
less, the expression of the 125-kDa isoform of ROR1 was
readily detected with the 4A5 mAb on formalin-fixed cells
via IHC, allowing us to examine tissue microarrays of
neoplastic and normal adult tissues for the isoform of
ROR1 associated with plasma membrane expression.
High proportions of each of various human cancers
expressed ROR1, which was not detectable on normal
tissue counterparts (Figure 1, C and D; see also Supple-
mental Figure S1C and Supplemental Table S8 at http://
ajp.amjpathol.org).2,4 Seventy-eight of 144 (54%) ovarian
cancers, 63 of 110 (57%) colon cancers, 49 of 64 (77%)
lung cancers, 52 of 58 (90%) lymphomas, 49 of 55 (89%)
Figure 1. ROR1 is expressed by a variety of different human cancer cells. A
(as indicated at the top of each lane) were probed with rabbit anti-ROR1-pept
(CHO-ROR1) were loaded as a positive control. Protein sizes are indicated on
or human cancer cell lines (786-0, A549, 2008, PANC1, SW620, or Capan-1; as
(open histograms) or IgG2b isotope control monoclonal antibody (mAb; shad
or adenocarcinomas of the colon or bladder of different patients were prob
control for the amounts of protein in each lysate. Protein sizes are indicated o
or neoplastic tissues were stained with 4A5 or control IgG2b. Tissue-bound 4
35 m (top left). D: The proportion of each tumor type found negative (ne
mAb to the tumor cells or low-to-moderate-level binding of the mAb on 
high-level staining of the tumor cells) staining for ROR1 are indicated by the
strong staining, the gray shading depicts the proportion of cases that have m
lack staining for ROR1 of each of the various human cancers examined, as in
tumor type is indicated in the parentheses.skin cancers, 38 of 48 (83%) pancreatic cancers, 35 of 48(73%) testicular cancers, 17 of 40 (43%) bladder cancers,
28 of 29 (96%) uterus cancers, 19 of 21 (90%) prostate
cancers, and 10 of 12 (83%) adrenal cancers had moder-
ate-to-strong staining with 4A5 (Figure 1D). Similar to the
formalin-fixed cytospin preparations of MDA-MB-231, the
staining of the tumor cells had both membrane and cyto-
plasmic ROR1, which was not observed on contiguous non-
neoplastic stromal tissue (Figure 1C).
The proportions of each tumor type that expressed ROR1
appeared variably distributed among subtypes of lung,
ovarian, or testicular cancers, but they were evenly distrib-
uted among subtypes of pancreatic cancer. The expression
of ROR1 was more prevalent among lung adenocarcino-
mas (34% moderate, 59% strong) than among lung squa-
noblots of immune precipitates with 4A5, using lysates of various cell lines
ody (top panel). Chinese hamster ovary (CHO) cells made to express ROR1
. Histograms in the bottom panel depict fluorescence of CHO, CHO-ROR1,
ed on the top of each panel) when stained with flurochrome-conjugated 4A5
grams). B: Protein lysates from CHO cells, CHO cells made to express ROR1,
anti-ROR1 antibodies (top row) or -actin (bottom row), which served to
t. C: Formalin-fixed, paraffin-embedded tissue microarray sections of normal
own in red, and the nuclear staining with hematoxylin is in blue. Scale bar 
A5 staining on all tumor cells), weak to moderate (low-level binding of the
tumor cells), or strong (moderate-level staining on 50% of tumor cells or
in each bar. The black shading represents the proportion of cases that have
staining, and the nonshaded open area indicates the proportion cases that
at the bottom of each bar. The number of different cases examined for each: Immu
ide antib
the left
indicat
ed histo
ed with
n the lef
A5 is sh
gative 4
50% of
shading
oderatemous cell carcinomas (17% moderate, 38% strong)
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had the smallest proportion of tumors that expressed ROR1
(20% moderate, 18% strong) among different subtypes of
ovarian cancers (Kruskal–Wallis test, P  0.001). We de-
tected high-level expression of ROR1 in seminoma, mixed
germ cell, and embryonal testicular carcinomas but not
teratomas or other types of testicular cancers (Kruskal–
Wallis test, P  0.001) (Figure 2).
Expression of ROR1 was associated with tumors that
had high-grade, less-differentiated histology. For ex-
ample, among ovarian serous papillary carcinomas
(n  69), a significantly higher proportion of carcino-
mas that were poorly differentiated expressed ROR1
(62%) than tumors that had grade 1 or 2 histology
(21%; Fisher’s exact test, P  0.0007). Similarly,
among pancreatic adenocarcinomas (n  24), a sig-
nificantly higher proportion of adenocarcinomas that
were poorly differentiated expressed ROR1 (100%)
than tumors that had grade 1 or 2 histology (54%;
Fisher’s exact test, P  0.0093) (Table 1).
Expression of ROR1 Is Associated with Higher
Levels of Activated AKT or CREB and Enhanced
Cell Growth
We performed cytoplasmic staining with the use of fluo-
rochrome-conjugated mAb specific for phosphoserine-
133 CREB (Alex 488-p-CREB) or PE-anti-p-AKT and ex-
amined the cells by flow cytometry. We found cancer cell
lines expressed p-AKT or p-CREB at different levels
Figure 2. The distribution of ROR1 in different histologic subtypes of vari-
ous cancers. The proportion of tumor cells found to have negative, moderate,
or strong staining for ROR1 are indicated in each of the various histologic
subtypes of various cancers examined as indicated at the bottom of each bar.
The number of different cases examined for each tumor type is indicated at
the bottom. Statistical significance of the differences was analyzed with the
Kruskal–Wallis test. Lung cancer tissues: Ad, adenocarcinoma; Sq, squamous
cell carcinoma. Ovarian cancer tissues: SP, serous papillary carcinoma; MC,
mucinous adenocarcinoma; EC, endometrioid adenocarcinoma; CC, clear
cell carcinoma. Pancreatic cancer tissues: Ad, adenocarcinoma; NC, neuroen-
docrine cancer. Testicular cancer tissues: Se, seminoma; MGC, mixed germ
cell; EC, embryonal carcinoma; Te, teratoma.(Figure 3A; see also Supplemental Table S9 at http://ajp.amjpathol.org), which significantly correlated with the
relative expression level of ROR1 in the cell lines (Figure
3B) (ROR1 versus p-AKT: Pearson r  0.7459, P 
0.0001; ROR1 versus p-CREB: Pearson r  0.7106, P 
0.0003).
We transfected MEC1 cells10 with either an expression
vector encoding human ROR1 or a control vector and
then selected stable transfectants in selection media
(Figure 3C). MEC1 cells typically have doubling time of
40 hours.10 However, MEC1 cells made to express
ROR1 had significantly greater proportions of cells in
S/G2/M phase than did control-transfected cells 16
hours after being transferred from serum-free medium
to complete growth medium (Figure 3C), implying that
expression of ROR1 increased the relative proportions
of cells undergoing cell division. Consistent with this,
we noted that ROR1 MEC1 cells had significantly
greater numbers of cells 48 hours after being trans-
ferred from serum-free medium than did comparably
seeded cultures of MEC1 cells that did not express
ROR1 (Figure 3D). Increased levels of p-AKT and p-
CREB also were observed in MEC1 cells made to ex-
press ROR1 relative to MEC1 cells transfected with the
control vector (Figure 3E).
We transduced the cells of various cancer cell lines
with vectors encoding shRNAs specific for ROR1 or a
random sequence (control shRNA). Cells transduced
with ROR1 shRNA, but not control shRNA, lost expression
of ROR1 mRNA and protein, as assessed via quantitative
PCR and immunoblot analysis (Figure 3F). ROR1-ex-
pressing cancer cells [eg, A549 cells11 (lung adenocar-
cinoma cells)] had higher proportions of apoptotic cells
and lower proportions of cells in S/G2/M phase when
transfected with ROR1 shRNA than when transfected with
control shRNA (Figure 3, G and H). Furthermore, ROR1-
expressing cancer cells [eg, A549, 200812 (ovarian car-
cinoma) or PANC113(pancreatic carcinoma) cells] had
poorer cell growth after transfection with ROR1 shRNA
than with control shRNA (Figure 3I). Finally, cancer cells
transfected with ROR1 shRNA had lower levels of p-
CREB and p-AKT than cells transfected with control
shRNA (Figure 3J).
We examined primary tumor tissues for expression of
ROR1, p-CREB, and p-AKT by immunohistochemistry.
We detected high-level expression of p-CREB in the nu-
cleus or p-AKT in the cytoplasm of many primary cancers
derived from the lung, ovary, or pancreas, but not in
Table 1. Correlation of ROR1 Expression with Poorly
Differentiated Ovarian Serous Papillary Carcinomas or
Pancreatic Adenocarcinomas
Tissue type
ROR1
negative,
n (%)
ROR1
positive,
n (%) P value*
Ovarian 0.0007
Grade 1 to 2 34 (79) 9 (21)
Grade 3 to 4 9 (38) 15 (62)
Pancreatic 0.0093
Grade 1 to 2 6 (46) 7 (54)
Grade 3 to 4 0 (0) 11 (100)*Determined with Fisher’s exact text.
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AJP December 2012, Vol. 181, No. 6Figure 3. Expression of ROR1 in cancer cell lines was associated with activation of AKT/CREB and silencing ROR1 expression impaired cell growth. A: Representative
fluorescence histograms of cancer cell lines (A549 and MOLT-4) stained with 4A5, p-AKT, or p-CREB (open histograms) or isotype-control mAb (shaded histograms),
respectively. Mean fluorescence intensity (MFI) was indicated on the top of each figure. B: Correlation of ROR1 expression level with either p-AKT or p-CREB in various
cancer cell lines. ROR1 versus p-AKT: Pearson r 0.7459, P 0.0001; ROR1 versus p-CREB: Pearson r 0.7106, P 0.0003. C:MEC1 cells stably transfected with either
empty vector (Vector) or vector encoding ROR1 (ROR1) were cultured in serum-free medium for 24 hours and then in full medium for 16 hours. Cell-cycle distributions were
determined by stainingwith propidium iodide (PI). Fluorescence histograms depicts cells stainedwith either 4A5 (open histograms) or isotype-control mAb (shaded histograms),
respectively. Representative histograms showDNA content in these cell lines. Live cellswere gatedwith the forward and side scatter parameters, FL2Wand FL2Aparameterswere
used to gate on single cells and to exclude doublets, and the FL2A channel was used tomeasureDNA content. The fraction of cells in each phase of the cell cyclewas determined
according to the Watson model, using the Cell-cycle analysis tool of the FlowJo software. The mean percentage of cells in S/G2/M SEM (n 3 experiments) is indicated
on the top of each figure.D: Control MEC1 cells or MEC1 expressing ROR1were cultured in serum-freemedium overnight. Equal numbers of these cells were then seeded
into separate, triplicate wells for culture in complete growth medium. The numbers of viable cells per well were assessed over time with the use of the WST-8 assay. The
y axis indicates the average number of viable cells per well on day 0, 1, 2, or 3 after initiation of culture in complete growth medium. The error bars indicate the SEM
for triplicate cultures. *P  0.05. E: Protein lysates from control MEC1 cells or MEC1 cells made to express ROR1 were probed with the antibodies as indicated. F: A549
tumor cells were transduced with vectors encoding control short hairpin RNA (Ct-shRNA) or ROR1 shRNA and then selected for stable expression of the shRNA. Lysates
of cells selected for stable expression of Ct-shRNA or ROR1 shRNA were examined for ROR1 or -actin via immunoblot analyses. Relative expression of ROR1 mRNA
quantitated by RT-PCR as indicated. The numbers on the y axis represent fold difference in ROR1 expression relative to GAPDH. Error bars indicate SEM (n  3
experiments). G: The mean proportion of apoptotic sub-G1 population in A549 cells transiently transfected with control shRNA (control) or ROR1 shRNAs (shRNA). The
error bars indicate the SE of triplicate samples. *P 0.05 multiple comparison test.H: The percentage of cells in S/G2/M of A549 cells expressing control shRNA or ROR1
shRNA are indicated. The error bars indicate the SE of triplicate samples. *P  0.05, multiple comparison test. I: Equal numbers of A549, 2008, or PANC1 cancer cells
made to express control shRNA or ROR1 shRNA, as indicated in the legend, were cultured and monitored for growth over time. Data represent average number of viable
cells assessed at times 0, 1, 2, or 3 days, using the WST-8 assay. The error bars indicate the SE of the mean for triplicate samples. *P  0.05, **P  0.01. J: Immunoblot
analysis of CREB phosphorylation at ser-133 (p-CREB), total CREB (t-CREB), AKT phosphorylation at ser-473 (p-AKT), total AKT (t-AKT), ROR1, or -actin for A549, 2008,
or PANC1 tumor cells that had or had not been silenced for ROR1, as indicated on the top of each panel.
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tissues (n  4) (Figure 4A). We found moderate-to-strong
staining of tumor cells for p-CREB or p-AKT in 43% or
54% of evaluated lung adenocarcinomas (n  44), 51%
or 13% of ovarian cancers (n  107), and 26% or 51% of
pancreatic cancers (n  57), respectively (Figure 4B).
We found that those tumors that had high levels of p-AKT
or p-CREB were significantly more likely to express ROR1
(see Supplemental Table S10 at http://ajp.amjpathol.org).
Detectable strong staining for p-AKT, p-CREB, or ROR1,
respectively, was found in 67, 89, or 152 of 208 tumors.
Moreover, 77 of the 152 (51%) tumor tissues that expressed
ROR1 had high-level p-CREB. In contrast, a significantly
lower proportion of 56 tumor tissues that lacked expression
of ROR1 (n  12; 21%) expressed p-CREB (P  0.0001,
Fisher’s exact test) (Figure 4C). Similarly 57 of the 152 (38%)
tumor tissues that expressed ROR1 also had high-level
p-AKT. However, a significantly lower proportion of 56 tumor
tissues that lacked expression of ROR1 (n  10; 18%)
expressed p-AKT (Fisher’s exact test, P  0.007) (Figure
4C). Finally, 37 of 152 (24%) tumor tissues that expressed
ROR1 also had high levels of both p-AKT and p-CREB
(Figure 4D).Discussion
The results presented here indicate that human cancers
derived from a diverse array of tissues expressed the
125-kDa isoform of ROR1 found on the plasma mem-
brane. In contrast, the nonneoplastic adult tissues corre-
sponding to these cancers lacked detectable ROR1 pro-
tein, as noted in prior studies.2,4 Two isoforms of ROR1
were detected in both cell lines and tumor tissues. How-
ever, 4A5, used for detection of ROR1 in formalin-fixed
tissue sections, detected only the 125-kDa isoform of
ROR1 that is expressed on the cell surface. We found that
different fixation solutions affected the apparent subcel-
lular location of ROR1, as has been noted for other pro-
teins (eg, GATA factors).14 We readily detected ROR1 on
the plasma membrane of paraformaldehyde-fixed cells,
but mostly cytoplasmic ROR1 in formalin-fixed cells. For
this reason, much of the surface/cytoplasmic staining of
4A5 on formalin-fixed tumor -tissue microarrays could be
because of ROR1 expressed by primary tumor cells at
the plasma membrane. Consistent with this notion, a va-
riety of different tumor cell lines were observed to express
Figure 4. Activation of AKT and CREB in lung,
ovarian, and pancreatic tumor tissues is associated
with ROR1 expression. A: Representative immu-
nohistochemistry staining for p-AKT and p-CREB
in different normal or cancer tissue specimens.
Tissue-bound p-AKT or p-CREB is shown in red,
and the nuclear staining with hematoxylin is in
blue. Scale bar  35 m (top left). B: The pro-
portion of tumor cells found to have negative,
weak-to-moderate, or strong staining for p-AKT or
p-CREB are indicated for each tumor type. The
number of different cases examined for each tu-
mor type is indicated in parentheses. Negative
indicates that there was no detectable monoclonal
antibody (mAb) staining for all tumor cells; mod-
erate indicates that there was low-level binding of
the mAb to all tumor cells or low-to-moderate-
level binding of the mAb on 50% of tumor cells;
strong indicates that there was moderate-level
staining on 50% of tumor cells or high-level
staining on tumor cells. C: Significant association
of ROR1 expression with p-CREB and/or p-AKT in
various human cancers (eg, lung, ovarian, or pan-
creatic neoplasms), as assessed with Fisher’s exact
test. D: The Venn diagram shows the distribution
and number of cases that express ROR (top left),
p-AKT (bottom), and/or p-CREB (top right) in
various human cancers (ie, lung, ovarian, and
pancreatic neoplasms). The numbers indicate the
numbers of cases that express ROR1, p-CREB, p-
AKT, or a combination.surface ROR1 in this and prior studies.8
The Expression of ROR1 in Human Cancers 1909
AJP December 2012, Vol. 181, No. 6We found that cancer cells that were poorly differenti-
ated with high-grade histology were more likely to ex-
press ROR1 than tumors with low-grade histology. This is
similar to what we observed among human breast ade-
nocarcinomas; expression of ROR1 was more common
among less-differentiated adenocarcinomas that lacked
expression of hormone receptors and human epidermal
growth factor receptor 2/Neu and that were associated
with more aggressive disease.8 The finding that ROR1
more commonly is expressed by tumors with high-grade
histology is similar to what other investigators have ob-
served for another onco-embryonic antigen, named 5T4,
which also appears to be expressed predominantly in
poorly differentiated tumors.15 Conceivably, expression
of such embryonic antigens might be a feature associ-
ated with tumor cells that have de-differentiated and/or
acquired biological features associated with embryogen-
esis.
We found expression of ROR1 was associated with
activation of AKT and CREB. These proteins are overex-
pressed and/or constitutively phosphorylated in a num-
ber of human cancers and are postulated to play a direct
role in tumor pathogenesis and progression.16–23 We
found a significant association between the expression
of ROR1 and activation of AKT in cancer cell lines or
primary tumor tissues. Similarly, primary lung, ovarian,
or pancreatic cancer tissues more frequently ex-
pressed p-CREB if they were ROR1 positive, as we
noted previously for breast adenocarcinomas.8,24
However, it should be noted that some tumors ex-
pressed ROR1 but lacked expression of p-CREB or
p-AKT. Conversely, some tumors expressed p-CREB
or p-AKT but lacked expression of ROR1. For such
tumors, the expression of ROR1 appears neither nec-
essary nor sufficient to provide for activation of AKT or
CREB. Nevertheless, there is a significant association
supported by functional studies showing that forced
expression or silencing of ROR1 can, respectively, en-
hance or suppress the levels of p-AKT/p-CREB in sev-
eral different cancer cell lines. As such, our studies
support the notion that ROR1 plays a role in the acti-
vation of AKT and/or CREB in a variety of different
cancers.
A prior study reported that many tumor cell lines ex-
pressed ROR1 and that the activity of ROR1 depended
on activation of the MET proto-oncogene.25 However, a
recent study found that ROR1 could enhance the survival
of tumor cells by either kinase-dependent or kinase-inde-
pendent pathways.9 Moreover, we found that the neo-
plastic cells in chronic lymphocytic leukemia cells do not
express MET,8 but they do express ROR1, which is im-
plicated in supporting chronic lymphocytic leukemia cell
survival.4,26 As such, the expression and/or activity of
ROR1 might not be predicated on the expression ofMET,
at least not in all human cancers.
In summary, the results presented here indicate that
many different human cancers express ROR1, which is
not expressed on most normal adult tissues. We found
ROR1 was more commonly expressed in tumors with
high-grade histology than in tumors with more differenti-
ated histology and identified a significant association be-tween the expression of ROR1 and p-AKT/p-CREB in
several different tumor types. Collectively, these studies
support the notion that ROR1 plays a functional role in
promoting tumor cell growth and suggest it may be a
target for development of therapies against a variety of
different human cancers.
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